L'intérêt à découvert pour Nuwellis donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Nuwellis. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Nuwellis (NASDAQ:NUWE) Stock, Rapport sur les intérêts à découvert

Nuwellis

Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.

Nuwellis Inc

WIIM

DuPont shares are trading higher after the company reported better-than-expected Q3 EPS and raised its FY24 adjusted EPS guidance.

APLS

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $143 to $149.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149

Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) short percent of float has risen 5.04% since its last report. The company recently reported that it has 70.94 million shares sold short, which is 1.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pfizer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814324_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pfizer has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pfizer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pfizer's peer group average for short interest as a percentage of float is 4.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Pfizer's Recent Short Interest

KKR's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) short percent of float has fallen 13.57% since its last report. The company recently reported that it has 11.63 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>KKR Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814319_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for KKR has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing KKR's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, KKR's peer group average for short interest as a percentage of float is 3.67%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into KKR's Recent Short Interest

PDD Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NYSE">PDD</a>) short percent of float has fallen 7.83% since its last report. The company recently reported that it has 32.98 million shares sold short, which is 4.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PDD Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814314_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PDD Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PDD Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PDD Holdings's peer group average for short interest as a percentage of float is 9.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Looking Into PDD Holdings's Recent Short Interest

Barclays analyst Steven Valiquette maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Equal-Weight and lowers the price target from $18 to $14.

Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $14

AHCO

AdaptHealth Corp shares are trading lower after the company reported worse-than-expected Q3 sales and revised its FY24 net revenue guidance

Cleveland-Cliffs shares are trading lower following worse-than-expected Q3 financial results.

LSCC

Lattice Semiconductor shares are trading lower following soft Q4 guidance.

Mission Produce shares are trading higher after the company raised its Q4 guidance above estimates.

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Equal-Weight and raises the price target from $7 to $8.

BCRX

Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $8

Barclays analyst Ryan Macwilliams maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Equal-Weight and raises the price target from $2 to $2.5.

EGHT

Barclays Maintains Equal-Weight on 8x8, Raises Price Target to $2.5

SKYT

SkyWater Technologies shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $9 to $12.

LUMN

Lumen Highlights Use Of Google Cloud For AI Services

Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.44) by 11.36 percent. This is a 34.48 percent decrease over losses of $(0.29) per share from the same period last year.

Earnings

Earnings Beats

INZY

Inozyme Pharma Q3 EPS $(0.39) Beats $(0.44) Estimate

Veru Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.
Highlights from the presentation: The objective of the meta-analysis was to determine the effects of enobosarm on body composition in older patients that had obesity who were enrolled in 4 previously conducted randomized clinical trials of enobosarm that measured body composition including Phase 2 older males and postmenopausal women, Phase 2 advanced cancer patients with muscle wasting, and two Phase 3 advanced lung cancer patients with cancer wasting.
Meta-analysis was conducted in older (≥60 years old) subjects with obesity (BMI ≥30), treated with enobosarm 3mg per day versus placebo, and who had a Day 84 (n= 60) and Day 147 (n=45) DEXA scans to assess body composition.
Results of DEXA scan assessments of body composition in older subjects with obesity: At Day 84, enobosarm 3mg treatment compared to placebo resulted in an absolute increase in lean mass (0.05 kg enobosarm vs -1.54 kg placebo) and absolute decrease in fat mass (-1.48 kg enobosarm vs placebo -0.35 kg).
At Day 147, enobosarm 3mg treatment compared to placebo resulted an absolute increase in lean mass (-0.79 kg enobosarm vs -1.77 kg placebo) and absolute decrease in fat mass (-2.05 kg enobosarm vs -0.05 kg placebo).
At Day 147, enobosarm 3mg treated subjects compared to placebo had greater total weight loss by DEXA scan (-2.93 kg for enobosarm and -2.11 kg for placebo).
Enobosarm was generally well-tolerated with no increase in gastrointestinal side effects.

Biotech

General

VERU

Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek

Monness, Crespi, Hardt analyst Gus Gala downgrades Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Neutral.

Downgrades

Monness, Crespi, Hardt Downgrades Marqeta to Neutral

Barclays analyst Andrew Mok maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $405 to $420.

Barclays Maintains Overweight on Cigna, Raises Price Target to $420

Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) shares are trading higher after its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740316/marathon-petroleum-corp-reports-third-quarter-2024-results" rel="noreferrer noopener">third-quarter results</a>.
Total revenues and other income of&nbsp;$35.4 billion&nbsp;topped the consensus of&nbsp;$32.8 billion.
Adjusted EBITDA was&nbsp;$2.49 billion&nbsp;for the quarter, compared with&nbsp;$5.71 billion in prior year quarter. Refining operating costs per barrel were&nbsp;$5.30&nbsp;versus&nbsp;$5.14&nbsp;a year ago.&nbsp;
Read: <a target="_blank" href="https://www.benzinga.com/news/24/11/41725310/marathon-petroleum-q3-earnings-preview-can-strong-sales-volume-offset-rising-costs" rel="noreferrer noopener">Marathon Petroleum Q3 Earnings Preview: Can Strong Sales Volume Offset Rising Costs?</a>
Refining &amp; Marketing refined product sales volume for the quarter was 3,685 mbpd&nbsp;(vs. 3,596 mbpd a year ago); Crude oil capacity utilization was&nbsp;94% (flat year over year).&nbsp;&nbsp;
Refining&nbsp;&amp; Marketing segment adjusted EBITDA declined to&nbsp;$1.053 billion from&nbsp;$4.373 billion a year ago due to lower market crack spreads.
Adjusted EPS for the quarter was&nbsp;$1.87,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">above the consensus of&nbsp;$0.98</a>.
As of September-end, Marathon Petroleum had&nbsp;$5.1&nbsp;billion&nbsp;of&nbsp;cash, cash equivalents,&nbsp;and&nbsp;short-term investments and&nbsp;$5 billion&nbsp;available&nbsp;on&nbsp;its bank revolving credit facility.
In the&nbsp;third quarter, the company returned around&nbsp;$3.0&nbsp;billion&nbsp;to shareholders, including&nbsp;$2.7&nbsp;billion&nbsp;in share repurchases and&nbsp;$273&nbsp;million&nbsp;in dividends. Through&nbsp;October 31, the company bought back an additional&nbsp;$0.5 billion&nbsp;of shares.
Additionally, the company&#8217;s board approved an incremental&nbsp;$5 billion&nbsp;share repurchase authorization. With the addition of this new authorization, Marathon Petroleum has&nbsp;$8.5 billion&nbsp;available under its share repurchase authorizations.&nbsp;
On&nbsp;October 30, the company increased its quarterly dividend to&nbsp;$0.91&nbsp;per share. The dividend is payable&nbsp;on December 10 to shareholders of record on&nbsp;November 20.&nbsp;&nbsp;&nbsp;
Outlook: Marathon Petroleum expects&nbsp;fourth-quarter Refining operating costs per barrel of&nbsp;$5.50 and&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">Refinery throughputs of 2,880 mbpd</a>.&nbsp;
Marathon Petroleum owns the general partner and majority limited partner interest in&nbsp;MPLX LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>), which reported&nbsp;third-quarter earnings per limited partner unit of&nbsp;$1.01, missing the consensus of&nbsp;$1.07, and revenues&nbsp;of&nbsp;$2.97 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740434/mplx-lp-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">missing the consensus of&nbsp;$3.09 billion</a>.&nbsp;MPLX returned&nbsp;$949 million of capital to unitholders in the quarter.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEO#BATS">IEO</a>) and&nbsp;VanEck Oil Refiners ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRAK#NYSE">CRAK</a>).
Price Action: MPC shares are up 2.80% at $149.00 premarket at the last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41295799/3-midstream-stocks-poised-to-benefit-as-geopolitical-tensions-rise" target="_blank" rel="noreferrer noopener">3 Midstream Stocks Poised to Benefit as Geopolitical Tensions Rise</a></li>
</ul>

Equities

Large Cap

Guidance

Dividends

Buybacks

Movers

CRAK

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

MPLX

Marathon Petroleum Q3 Earnings: Outpaces Expectations, Powers Up Shareholder Rewards & More

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!



Moving stocks this morning are clinical trial updates, an acquisition deal and a public offering.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Planet Image (NASDAQ:<a href="https://investorplace.com/stock-quotes/yibo-stock-quote/">YIBO</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Lipella Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) shares are soaring over 58% after <a href="https://www.stocktitan.net/news/LIPO/lipella-pharmaceuticals-initiates-phase-2a-trial-for-lp-310-in-oral-kdvluw7gmnv7.html">initiating a Phase 2a clinical trial</a>.</li>



<li>Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is surging more than 44% with <a href="https://www.nasdaq.com/press-release/cognition-therapeutics-proof-concept-phase-2-shine-trial-demonstrates-consistent">positive Phase 2 study results</a>.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are gaining over 32% following a <a href="https://www.nasdaq.com/press-release/bestgrowthstockscom-issues-comprehensive-analysis-tivic-health-systems-potential">breakdown of its potential catalysts</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is increasing more than 22% with the release of <a href="https://www.nasdaq.com/press-release/longeveronr-presents-study-results-clear-mind-phase-2a-clinical-trial-lomecel-btm">Phase 2a study results</a>.</li>



<li>Pineapple Financial (NYSEMKT:<a href="https://investorplace.com/stock-quotes/papl-stock-quote/">PAPL</a>) shares are rising 22% without any clear news this morning.</li>



<li>Cepton (NASDAQ:<a href="https://investorplace.com/stock-quotes/cptn-stock-quote/">CPTN</a>) stock is climbing over 19% on <a href="https://www.stocktitan.net/news/CPTN/cepton-signs-definitive-agreement-to-be-acquired-by-7cwu0k4o8p93.html">an acquisition agreement</a>.</li>



<li>Ambipar Emergency (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ambi-stock-quote/">AMBI</a>) shares are jumping more than 18% this morning.</li>



<li>BurgerFi (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfi-stock-quote/">BFI</a>) stock is heading over 16% higher as it <a href="https://investorplace.com/2024/07/why-is-burgerfi-international-bfi-stock-up-71-today/">continues a recent rally</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) shares are up more than 15% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>vTv Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) stock is plummeting over 44% after announcing the Food and Drug Administration&nbsp;(FDA) <a href="https://www.nasdaq.com/press-release/vtv-therapeutics-announces-cadisegliatin-program-type-1-diabetes-placed-clinical-hold">placed a clinical hold</a> on one of its trials.</li>



<li>CERo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are diving more than 33% despite a lack of news this morning.</li>



<li>Treasure Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/tgl-stock-quote/">TGL</a>) stock is tumbling over 25% on Monday morning.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) shares are taking a more than 17% beating after <a href="https://www.globenewswire.com/news-release/2024/07/27/2919920/0/en/LuxUrban-Hotels-Announces-Pricing-of-Public-Offering-of-Securities.html">pricing a public offering</a>.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is dropping over 11% without any clear news to report.</li>



<li>Phio Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/phio-stock-quote/">PHIO</a>) shares are sliding more than 11% this morning.</li>



<li>Notable Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntbl-stock-quote/">NTBL</a>) stock is decreasing over 10% on Monday morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) shares are falling more than 9% after a Friday rally.</li>



<li>Carbon Revolution (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/">CREV</a>) stock is slipping over 9% after jumping Friday <a href="https://finance.yahoo.com/news/carbon-revolution-supplies-carbon-fiber-011000695.html">on a wheels deal</a>.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-29th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Nuwellis Q2 Earnings Preview

Nuwellis GAAP EPS of -$18.85 misses by $10.61, revenue of $2.19M beats by $0.19M

Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) just reported results for the second quarter of 2024.<ul><li>Nuwellis reported earnings per share of -$4.68. This was above the analyst estimate for EPS of -$8.24.</li><li>The company reported revenue of $2.19 million.</li><li>This was 9.70% better than the analyst estimate for revenue of $2.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nuwe-stock-earnings-nuwellis-for-q2-of-2024/">NUWE Stock Earnings: Nuwellis Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NUWE Stock Earnings: Nuwellis Beats EPS, Beats Revenue for Q2 2024

Maxim Group analyst Anthony Vendetti maintained a Hold rating on Nuwellis (NUWE – Research Report) yesterday. The company's shares closed yesterday...

Maxim Group Keeps Their Hold Rating on Nuwellis (NUWE)

Nuwellis to sell 496,901 shares at $1.845 in registered direct offering

Nuwellis (NUWE) has issued an update. Nuwellis, Inc. has launched a financial venture, selling over 483,000 shares at $1.8450 each, alongside warra...

Nuwellis Secures Funds Through Shares and Warrants Offering

Nuwellis shares nearly doubled on higher than expected Q3 prelim revenue

Nuwellis (NUWE) announces that the Centers for Medicare and Medicaid Services, CMS, will reassign the Aquadex ultrafiltration code to the outpatien...

Nuwellis receives increased reimbursement rate for Aquadex SmartFlow therapy

AMBI

CERO

CGTX

CPTN

CREV

INVO

LGVN

LIPO

LUXH

NTBL

NUWE

NUWEW

PAPL

PHIO

TIVC

VCNX

VTVT

YIBO

Press Releases

Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions

Nuwellis, Inc. Announces Second Quarter 2024 Financial Results

Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Health Care

New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

Nuwellis Welcomes University of Iowa Health Care Stead Family Children's Hospital as Newest Pediatric Customer

Economics

Nuwellis Announces Preliminary Results for Third Quarter of 2024

Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

Peraso Inc. (NASDAQ: PRSO) Volume Soars as SAF Tehnika Adopts Technology Across a $3.4B Market North America & Europe – More Stocks Inside!

Comments

Nuwellis

Intérêt court

Nuwellis (NASDAQ:NUWE) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL